We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Non-Invasive Biosensor Facilitates Early Kidney Disease Detection

By LabMedica International staff writers
Posted on 07 Nov 2024
Print article
Image: The sensor measures SDMA levels in urine with high accuracy (Photo courtesy of ’’Kidney Cross Section’’ Artwork by Holly Fischer)
Image: The sensor measures SDMA levels in urine with high accuracy (Photo courtesy of ’’Kidney Cross Section’’ Artwork by Holly Fischer)

Traditionally, kidney function has been assessed by measuring blood creatinine levels, which reflect muscle breakdown. Elevated creatinine levels may indicate that the kidneys are not effectively filtering waste. However, these levels can be influenced by an individual's muscle mass and typically rise significantly only after more than 75% of kidney function has been compromised. In contrast, symmetric dimethylarginine (SDMA), a byproduct of protein metabolism, has emerged as a more reliable marker of kidney health. SDMA builds up in the bloodstream because it is not metabolized and is primarily excreted by the kidneys. Measuring SDMA in urine offers a more precise assessment of kidney function. Unlike creatinine, SDMA levels can increase with mild kidney impairment (25–40% loss) and are not significantly affected by muscle mass. Now, a new biosensor utilizing affinity peptides has been developed to accurately measure SDMA levels in urine, providing a practical and cost-effective solution for early diagnosis and monitoring of kidney disease.

The biosensor created by researchers at Chung Ang University (Seoul, Republic of Korea) detects SDMA levels in urine, offering a non-invasive alternative to blood tests, which allows for earlier detection and management of kidney disease. At the core of this biosensor are small, linear peptides that specifically bind to SDMA. These peptides were synthesized and attached to a Ni-Cr layered double hydroxide with graphene oxide (NCL-GO) nanostructure, which is integrated onto gold (Au) electrodes. The sensor was designed using a drop-cast method, where the gold electrodes were coated with a solution containing NCL-GO and left to dry, resulting in a stable coating of peptide-functionalized electrodes (termed peptide/NCL-GO/Au).

The unique two-dimensional structure of NCL-GO consists of interconnected Ni-Cr layered double hydroxide nanosheets and conductive graphene oxide nanosheets. This configuration creates porous, well-connected networks that enhance charge transfer and molecular diffusion, thereby improving the conductivity and surface area of the electrodes. This design amplifies the interaction between the peptides and SDMA, enhancing the sensor's detection capabilities. While other SDMA detection methods, such as chromatography, provide higher sensitivity, this new electrochemical biosensor is user-friendly and does not necessitate sophisticated equipment. As a result, it is more affordable and practical for various environments, including small clinics, remote areas, and resource-limited settings. According to the study published in the journal Biosensors and Bioelectronics, the biosensor features a simple design and delivers rapid results, making it a suitable option for routine health assessments and monitoring.

“Since kidney disease is often diagnosed very late, we aim to develop a sensing tool that patients or clinicians can use to easily monitor kidney health for effective treatment, enabling timely interventions and potential for long-term outcomes,” said Professor Jong Pil Park from Chung-Ang University who led the research team. “The sensor could facilitate earlier diagnosis, advanced monitoring of kidney function, and improved treatment outcomes for millions of patients worldwide. Moreover, our platform technology has the potential to be adapted for detecting other biomarkers, making it a versatile tool applicable across various areas of healthcare.”

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.